NEW YORK (GenomeWeb) – KineMed has signed a strategic deal with Pfizer to discover and develop new proteomics-based biomarkers using KineMed's protein activity kinetics tracking technology, the California-based company announced today.

Under the terms of the agreement, Pfizer has licensed KineMed's proteomics platform and the rights to discover, develop, and commercialize biomarkers. The partners will work together on discovery, while Pfizer will be responsible for developing and commercializing any biomarkers or companion diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.